OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line

     OncoGenex Announces Fast Track Designation Granted for Custirsen in
Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3
   AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014

BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the
U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
the investigation of custirsen when administered in combination with
cabazitaxel/prednisone for the treatment of men with metastatic
castrate-resistant prostate cancer (CRPC) following prior treatment with a
docetaxel-containing regimen.

Fast track is a process designed to facilitate the development, and expedite
the review, of drugs to treat serious conditions and fill an unmet medical
need. The purpose is to get important new drugs to the patient earlier.

The international, randomized, open-label Phase 3 AFFINITY trial is designed
to evaluate if custirsen, when combined with second-line chemotherapy
cabazitaxel and prednisone, has the potential to improve survival outcomes for
prostate cancer patients compared to second-line chemotherapy alone. AFFINITY
will enroll approximately 630 men and is expected to complete enrollment in
the second half of 2014.

Custirsen has also received Fast Track designation from theFDA for treatment
of patients with metastatic non-small cell lung cancer as part of the Phase 3
ENSPIRIT trial and for men with metastatic CRPC as part of the Phase 3 SYNERGY
trial. Enrollment in the ENSPIRIT trial is ongoing and top-line survival
results from SYNERGY are expected by mid-2014.

For more information on the AFFINITY trial, including centers currently
enrolling patients, please visit www.prostatecancerstudy.com.

About Custirsen
Custirsen is an experimental drug that is designed to block the production of
the protein clusterin, which may play a fundamental role in cancer cell
survival and treatment resistance. Clusterin is upregulated in tumor cells in
response to treatment interventions such as chemotherapy, hormone ablation and
radiation therapy and has been found to be overexpressed in a number of
cancers, including prostate, lung, breast and bladder. Increased clusterin
production has been linked to faster rates of cancer progression, treatment
resistance and shorter survival duration. By inhibiting clusterin, custirsen
is designed to alter tumor dynamics, slowing tumor growth and resistance to
partner treatments, so that the benefits of therapy, including survival, may
be extended.

As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to
294 patients with various types of cancer. The majority of adverse events were
mild. The most common adverse events associated with custirsen consisted of
flu-like symptoms. The most common serious adverse events (SAE) associated
with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea.
Each SAE event was observed in approximately 2%-4% of patients.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development. OncoGenexandTeva Pharmaceutical
Industries Ltd. (NYSE: TEVA)have entered a global collaboration and licensing
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. Apatorsen is
in Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com and at the
company's Twitter account: https://twitter.com/OncoGenex_IR.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning the potential
regulatory timelines and the potential market opportunity for our product
candidates. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. These statements
are based on management's current expectations and beliefs and are subject to
a number of risks, uncertainties and assumptions that could cause actual
results to differ materially from those described in the forward-looking
statements, including, among others, the risk that our product candidates will
not receive regulatory approval as or when expected, the risk that our product
candidates will not successfully be commercializedand the other factors
described in our risk factors set forth in our filings with the Securities and
Exchange Commission from time to time, including the Company's Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no
obligation to update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof, other than as
may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.

Contact: Media: Jaime Welch, jwelch@oncogenex.com, 604-630-5403; or Investor
Relations: Susan Specht, sspecht@oncogenex.com, 425-686-1535
Press spacebar to pause and continue. Press esc to stop.